<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00920153</url>
  </required_header>
  <id_info>
    <org_study_id>LH 2007</org_study_id>
    <nct_id>NCT00920153</nct_id>
  </id_info>
  <brief_title>Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma</brief_title>
  <official_title>Study Characterizing the Impact of Different Therapeutic Strategies on Event Occurrence at 2 Years, 5 Years, 10 Years, and 15 Years, According to Prognostic Groups in Patients With Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
      cells, either by killing the cells or by stopping them from dividing. Giving drugs in
      different combinations may kill more cancer cells. It is not yet know which treatment regimen
      is more effective in treating Hodgkin lymphoma.

      PURPOSE: This phase III trial is studying three different therapy regimens to compare how
      well they work in treating patients with previously untreated Hodgkin lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate event-free survival.

      Secondary

        -  Evaluate overall survival.

        -  Evaluate the prognostic value of FDG-PET scanning.

        -  Evaluate progression-free survival.

        -  Evaluate tolerability.

        -  Evaluate rate of relapse.

      OUTLINE: This is a multicenter study. Patients are assigned to 1 of 3 treatment groups
      according to prognosis.

        -  Group 1 (favorable prognosis): Patients receive ABVD chemotherapy comprising doxorubicin
           hydrochloride IV, bleomycin sulfate IV, vincristine sulfate IV, dacarbazine IV, and
           methylprednisolone IV on days 1 and 14. Treatment repeats every 28 days for 2 courses.
           Patients then undergo PET scan for evaluation of response. Patients receive additional
           treatment according to response.

             -  Favorable response: Patients with favorable response receive 1 additional course of
                ABVD chemotherapy.

             -  Unfavorable response: Patients with unfavorable response receive 1 course of VABEM
                chemotherapy comprising vindesine IV continuously on days 1-5, doxorubicin
                hydrochloride IV continuously on days 1-3, carmustine IV on day 3, etoposide IV on
                days 3-5, and methylprednisolone IV on days 1-5.

        -  Group 2 (intermediate prognosis): Patients receive 2 courses of ABVD chemotherapy.
           Patients then undergo PET scan for evaluation of response. Patients receive additional
           treatment according to response.

             -  Favorable response: Patients with favorable response receive 4 additional courses
                of ABVD chemotherapy.

             -  Unfavorable response: Patients with unfavorable response receive VABEM
                chemotherapy. Treatment with VABEM chemotherapy repeats every 28 days for 2
                courses.

        -  Group 3 (poor prognosis): Patients receive 2 courses of VABEM chemotherapy. Patients
           then undergo PET scan for evaluation of response. Patients receive additional treatment
           according to response.

             -  Favorable response: Patients with favorable response receive 1 additional course of
                VABEM chemotherapy.

             -  Unfavorable response: Patients with unfavorable response receive CEO chemotherapy
                comprising cisplatin IV continuously on days 1-3, gemcitabine hydrochloride IV on
                days 1 and 8, and oral dexamethasone once daily on days 1-4. Treatment repeats
                every 21 days for 3 courses. Patients then undergo PET scan. Patients receive
                additional treatment according to response.

                  -  Favorable response: Patients with favorable response receive BEAM chemotherapy
                     comprising carmustine IV on day -7, etoposide IV and cytarabine IV on days -6
                     to -3, and melphalan IV on day -2. Patients then undergo autologous stem cell
                     transplantation on day 0.

                  -  Unfavorable response: Patients with unfavorable response receive MINE
                     chemotherapy comprising mitoguazone IV, vinorelbine ditartrate IV, and
                     ifosfamide IV on days 1-5 and etoposide IV on days 1-3. Treatment repeats
                     every 28 days for 3 courses. Patients then undergo allogeneic or autologous
                     stem cell transplantation.

      Patients with favorable response or a &quot;bulky&quot; mass at diagnosis may also undergo
      radiotherapy.

      After completion of study treatment, patients are followed periodically for 15 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Other new drugs
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>treatments evaluation</time_frame>
    <description>event free survival</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">442</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Group 1 (favorable prognosis)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ABVD and VABEM chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (intermediate prognosis)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ABVD and VABEM chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 (poor prognosis)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive VABEM, CEO, BEAM, and MINE chemotherapy. Patients also undergo allogeneic or autologous stem cell transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bleomycin sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 1 (favorable prognosis)</arm_group_label>
    <arm_group_label>Group 2 (intermediate prognosis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABVD regimen</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 1 (favorable prognosis)</arm_group_label>
    <arm_group_label>Group 2 (intermediate prognosis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 1 (favorable prognosis)</arm_group_label>
    <arm_group_label>Group 2 (intermediate prognosis)</arm_group_label>
    <arm_group_label>Group 3 (poor prognosis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 3 (poor prognosis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 3 (poor prognosis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dacarbazine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 1 (favorable prognosis)</arm_group_label>
    <arm_group_label>Group 2 (intermediate prognosis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Group 3 (poor prognosis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 1 (favorable prognosis)</arm_group_label>
    <arm_group_label>Group 2 (intermediate prognosis)</arm_group_label>
    <arm_group_label>Group 3 (poor prognosis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 1 (favorable prognosis)</arm_group_label>
    <arm_group_label>Group 2 (intermediate prognosis)</arm_group_label>
    <arm_group_label>Group 3 (poor prognosis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 3 (poor prognosis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 3 (poor prognosis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 3 (poor prognosis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 1 (favorable prognosis)</arm_group_label>
    <arm_group_label>Group 2 (intermediate prognosis)</arm_group_label>
    <arm_group_label>Group 3 (poor prognosis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoguazone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 3 (poor prognosis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 1 (favorable prognosis)</arm_group_label>
    <arm_group_label>Group 2 (intermediate prognosis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vindesine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 1 (favorable prognosis)</arm_group_label>
    <arm_group_label>Group 2 (intermediate prognosis)</arm_group_label>
    <arm_group_label>Group 3 (poor prognosis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine tartrate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 3 (poor prognosis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Patients undergo allogeneic stem cell transplantation</description>
    <arm_group_label>Group 3 (poor prognosis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous hematopoietic stem cell transplantation</intervention_name>
    <description>Patients undergo autologous stem cell transplantation</description>
    <arm_group_label>Group 3 (poor prognosis)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          -  Life expectancy &gt; 3 months

          -  LVEF normal

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Must be able to undergo follow-up for â‰¥ 15 years

          -  No impaired cardiac function that would preclude the administration of an
             anthracycline

          -  No other prior or concurrent malignancy, except for carcinoma in situ of the cervix or
             basal cell skin cancer

          -  No respiratory, kidney, or liver failure or other severe clinical insufficiency that
             would preclude study treatment

          -  No HIV or hepatitis B virus positivity

          -  No other disease that would preclude treatment with chemotherapy or radiotherapy

        EXCLUSION CRITERIA:

          -  No concurrent participation in another experimental trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Delphine Senecal</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organization</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FILO French Innovative Leukemia Organization</name>
      <address>
        <city>Tours Cedex</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2009</study_first_submitted>
  <study_first_submitted_qc>June 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2009</study_first_posted>
  <last_update_submitted>September 15, 2016</last_update_submitted>
  <last_update_submitted_qc>September 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I adult Hodgkin lymphoma</keyword>
  <keyword>stage II adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Vindesine</mesh_term>
    <mesh_term>Mitoguazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

